Oral testosterone undecanoate, LPCN 1021 + Topical testosterone gel 1.62 %

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Male Hypogonadism

Conditions

Male Hypogonadism

Trial Timeline

Feb 1, 2014 → May 1, 2015

NCT ID

NCT02081300

About Oral testosterone undecanoate, LPCN 1021 + Topical testosterone gel 1.62 %

Oral testosterone undecanoate, LPCN 1021 + Topical testosterone gel 1.62 % is a phase 3 stage product being developed by Lipocine for Male Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT02081300. Target conditions include Male Hypogonadism.

What happened to similar drugs?

3 of 20 similar drugs in Male Hypogonadism were approved

Approved (3) Terminated (0) Active (17)

✅Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved

✅CFA + rFSHMerckApproved

✅Treatment A + Blood samples for the analysis of sildenafil in plasma + Treatment B + Treatment CPfizerApproved

🔄Gemcitabine + liposomal doxorubicinEli LillyPhase 3

🔄Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3

🔄Abemaciclib 50 MG; 150mg 1-0-1 per osEli LillyPhase 3

🔄SHR6390 + placeboJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02081300	Phase 3	Completed	Feb 1, 2014	May 1, 2015	Male Hypogonadism

Competing Products

20 competing products in Male Hypogonadism

See all competitors

Product	Company	Stage	Hype Score
Fulvestrant	Dr. Reddy's Laboratories	Pre-clinical	19
ENZ215 + EU Sourced Prolia + US Sourced Prolia	Alkem Laboratories	Phase 1	29
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	39
Gemcitabine + liposomal doxorubicin	Eli Lilly	Phase 3	40
[14C]-LY3549492 + LY3549492 + [14C]-LY3549492	Eli Lilly	Phase 1	29
CT-P41 + EU-approved Prolia	Celltrion	Phase 1	29
CT-P55 + US-licensed Cosentyx + EU-approved Cosentyx	Celltrion	Phase 1	29
CT-P52	Celltrion	Phase 1	36
CT-P43 + CT-P43	Celltrion	Phase 1	29
Telmisartan + Amlodipine + Rosuvastatin	Yuhan	Phase 1	29
ASP3325 + Placebo	Astellas Pharma	Phase 1	29
TRK-100STP	Astellas Pharma	Phase 1	29
Ensitrelvir	Shionogi	Phase 1	29
E6011 + E6011 Matching Placebo	Eisai	Phase 1	29
E6130 + Placebo	Eisai	Phase 1	29
Eribulin Injection [Halaven] + Paclitaxel injection	Eisai	Approved	39
E3112	Eisai	Phase 1	29
E2022 Tape Formulation	Eisai	Phase 1	29
Placebo + E3112	Eisai	Phase 1	29
[14C]-E6007	Eisai	Phase 1	29